Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Nature SciCafe

Summary

Speakers

Mitchell S. Bloom

Theresa C. Kavanaugh

Related Content

Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigation

MDL Panel Grants Transfer of Aflibercept BPCIA Case

FDA Approves BMS and J&J CAR-T Cell Therapies for the Earlier Treatment of Multiple Myeloma

Janssen v. Teva: Not an April Fool’s Day Joke for Life Sciences Companies

FDA Approves New Indication for AstraZeneca and Daiichi Sankyo’s Cancer Drug ENHERTU

A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond

A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond

REGENXBIO and Sarepta Agree to Stay Litigation Pending Outcome of Sarepta’s IPR Petition

Goodwin is Number One in the Q1 2024 League Table Rankings

Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval

Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma

Goodwin Represents the Underwriters in PACS Group $450 Million IPO

Goodwin Advises Exclusive Placement Agent in Acrivon Therapeutics’ $130 Million Private Placement

Alpine Immune Sciences To Be Acquired by Vertex Pharmaceuticals For $4.9 Billion

Goodwin Picks Up Tech Team, Eyeing AI-Fueled Rebound (Bloomberg Law)

Deal Watch: M&A (Law.com)

Life Sciences